IP Library Granted Patent US 9,840,516
Granted Patent B2
US 9,840,516 · App. 14/511,425 · Granted Dec 12, 2017

Substituted quinazolines as inhibitors of KRAS G12C

Inventors: Liansheng Li (San Diego, CA); Jun Feng (San Diego, CA); Tao Wu (Carlsbad, CA); Pingda Ren (San Diego, CA); Yi Liu (San Diego, CA); Yuan Liu (San Diego, CA); Yun Oliver Long (San Diego, CA)
Assignee: ARAXES PHARMA LLC
C07D495/04C07D215/46C07D215/54C07D217/22C07D239/84C07D239/94C07D239/95C07D241/44C07D401/12C07D403/04C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,840,516
App. No.
14/511,425
Granted
Dec 12, 2017
Kind
B2
Abstract

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R 1 , R 2a , R 3a , R 3b , R 4a , R 4b , G 1 , G 2 , L 1 , L 2 , m 1 , m 2 , A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Claims (57)

1. A compound having the following structure (I):

or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein:

represents a double or triple bond;

Q is —C(═O)—, —C(═NR 8′ )—, —NR 8 C(═O)—, —S(═O) 2 — or —NR 8 S(═O) 2 —;

Y is CR 6 ;

X is N;

Z is N;

L 1 is a bond;

L 2 is a bond or alkylene;

R′ is R 1 and R″ is R 2c ; or R′ is H and R″ is R 1 ;

R 1 is heterocyclyl, heteroaryl or aryl;

R 2a , R 2b and R 2c are each independently H, halo, —OH, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl, heteroaryl or aryl;

R 3a and R 3b are, at each occurrence, independently H, —OH, —NH 2 , —CO 2 H, halo, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkynyl, hydroxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl;

R 4a and R 4b are, at each occurrence, independently H, —OH, —NH 2 , —CO 2 H, halo, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkynyl, hydroxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl;

R 6 is H, cyano, cyanoalkyl, amino, aminylalkyl, aminylalkylaminyl, aminylcarbonyl, aminylsulfonyl, —CO 2 NR a R b , alkylaminyl, haloalkylaminyl, hydroxyalkylaminyl, amidinylalkyl, amidinylalkoxy, amidinylalkylaminyl, guanidinylalkyl, guanidinylalkoxy, guanidinylalkylaminyl, C 1 -C 6 alkoxy, aminylalkoxy, alkylaminylalkoxy, alkylcarbonylaminylalkoxy, C 1 -C 6 alkyl, heterocyclyl, heterocyclyloxy, heterocyclylalkyloxy, heterocyclylaminyl, heterocyclylalkylaminyl, heteroaryl, heteroaryloxy, heteroarylalkyloxy, heteroarylaminyl, heteroarylalkylaminyl, aryl, aryloxy, arylaminyl, arylalkylaminyl or arylalkyloxy;

R a and R b are each independently H or C 1 -C 6 alkyl; or

R a and R b join to form a carbocyclic or heterocyclic ring;

R 8 is H, C 1 -C 6 alkyl or hydroxyalkyl;

R 8′ is H, —OH, cyano or C 1 -C 6 alkyl;

indicates a double bond;

when is a double bond then R 9 and R 10 are each independently H, cyano, carboxy, C 1 -C 6 alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, heteroaryl or hydroxyalkyl or R 9 and R 10 join to form a carbocyclic or heterocyclic ring; and

when is a triple bond then R 9 is absent and R 10 is H, C 1 -C 6 alkyl, aminylalkyl, alkylaminylalkyl or hydroxyalkyl,

provided that at least one of R 2a , R 2b or R 2c is not H when R 1 is pyridyl, and wherein each alkylene, heterocyclyl, heteroaryl, aryl, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, alkoxycarbonyl, C 3 -C 8 cycloalkyl, C 2 -C 6 alkynyl, hydroxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl, aminylcarbonyl, aminylalkylaminyl, aminylcarbonyl, aminylsulfonyl, carbocyclic ring, heterocyclic ring, alkylaminyl, haloalkylaminyl, hydroxyalkylaminyl, amidinylalkyl, amidinylalkoxy, amidinylalkylaminyl, quanidinylalkyl, guanidinylalkoxy, guanidinylalkylaminyl, aminylalkoxy, alkylaminylalkoxy, alkylcarbonylaminylalkoxy, heterocyclyloxy, heterocyclylalkyloxy, heterocyclylaminyl, heterocyclylalkylaminyl, heteroaryloxy, heteroarylalkyloxy, heteroarylaminyl, heteroarylalkylaminyl, aryloxy, arylaminyl, arylalkylaminyl and arylalkyloxy is optionally substituted with one or more substituents selected from the group consisting of aminyl, cyano, hydroxy, imino, nitro, oxo, thioxo, halo, aminylsulfonyl, aminylcarbonyl, C 1 -C 12 alkyl, C 1 -C 6 alkylaminylcarbonyl, aminylcarbonylC 1 -C 6 alkyl, C 1 -C 12 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkoxyalkyl, C 1 -C 6 haloalkoxyalkyl, cyanoC 1 -C 6 alkyl, C 1 -C 6 alkylcycloalkyl, C 1 -C 6 alkylhetercycloalkyl, C 2 -C 6 alkynyl, C 1 -C 6 alkylaminyl, C 1 -C 6 alkylcarbonylaminyl, C 1 -C 6 hydroxyalkyl, C 2 -C 6 alkenylcarbonylaminyl, C 1 -C 6 thioalkyl, aryl, aralkyl, C 3 -C 8 cycloalkyl optionally substituted with cyano, C 3 -C 8 cycloalkylalkyl, aminylcarbonylC 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkylaminylcarbonyl, C 3 -C 8 fused cycloalkyl, heterocycyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and heteroarylalkyl.

2. The compound of claim 1 , wherein the compound has the following structure (I′f):

3. The compound of claim 1 , wherein the compound has the following structure (I′j):

4. The compound of claim 1 , wherein L 2 is a bond.

5. The compound of claim 1 , wherein R 1 is optionally substituted aryl.

6. The compound of claim 5 , wherein R 1 is substituted with one or more substituents.

7. The compound of claim 6 , wherein the substituents are selected from the group consisting of halo, cyano, cyanoC 1 -C 6 alkyl, cyanoC 3 -C 8 cycloalkyl, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkylcycloalkyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylaminyl, C 1 -C 6 alkylcarbonylaminyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxyalkyl, aminylsulfonyl, aminylcarbonyl, aminylcarbonylC 1 -C 6 alkyl, aminylcarbonylC 3 -C 8 cycloalkyl, C 1 -C 6 alkylaminylcarbonyl, C 3 -C 8 cycloalkylaminylcarbonyl, C 3 -C 8 cycloalkylalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 fused cycloalkyl and heteroaryl.

8. The compound of claim 7 , wherein the substituents are selected from the group consisting of fluoro, chloro, bromo, cyano, hydroxy, hydroxymethyl, methoxy, methoxymethyl, methyl, ethyl, isopropyl, difluoromethyl, trifluoromethyl, aminylcarbonyl and cyclopropyl.

9. The compound of claim 1 , wherein R 1 is aryl substituted with one or more substituents selected from the group consisting of halo, cyano, cyanoC 1 -C 6 alkyl, cyanoC 3 -C 8 cycloalkyl, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkylcycloalkyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylaminyl, C 1 -C 6 alkylcarbonylaminyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxyalkyl, aminylsulfonyl, aminylcarbonyl, aminylcarbonylC 1 -C 6 alkyl, aminylcarbonylC 3 -C 8 cycloalkyl, C 1 -C 6 alkylaminylcarbonyl, C 3 -C 8 cycloalkylaminylcarbonyl, C 3 -C 8 cycloalkylalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 fused cycloalkyl and heteroaryl, and each of R a , R b , R 2a , R 2b , R 2c , R 3a , R 3b , R 4a , R 4b , R 6 , R 8 , R 8′ , R 9 , R 10 and L 2 are unsubstituted.

10. The compound of claim 5 , wherein R 1 is phenyl.

11. The compound of claim 5 , wherein R 1 has one of the following structures:

12. The compound of claim 1 , wherein R 1 is optionally substituted heterocyclyl or optionally substituted heteroaryl.

13. The compound of claim 12 , wherein R 1 is substituted with one or more substituents.

14. The compound of claim 13 , wherein the substituents are selected from the group consisting of halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy and C 2 -C 6 alkenylcarbonylaminyl.

15. The compound of claim 13 , wherein the substituents are selected from the group consisting of fluoro, chloro, amino and methyl.

16. The compound of claim 1 , wherein R 1 is heteroaryl substituted with one or more substituents selected from the group consisting of halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy and C 2 -C 6 alkenylcarbonylaminyl, and each of R a , R b , R 2a , R 2b , R 2c , R 3a , R 3b , R 4a , R 4b , R 6 , R 8 , R 8′ , R 9 , R 10 and L 2 are unsubstituted.

17. The compound of claim 12 , wherein R 1 is thiophenyl, pyridinyl, pyridinonyl, pyrimidinyl, benzooxazolyl, benzoisoxazolyl, benzodioxazolyl, benzoimidazolyl, quinolinyl, quinolinonyl, dihydroquinolinonyl, tetrahydroquinolinyl, quinazolinyl, indazolyl, indolinonyl, benzothiophenyl or dihydrobenzodioxinyl.

18. The compound of claim 12 , wherein R 1 has one of the following structures:

19. The compound of claim 1 , wherein R 2a is halo.

20. The compound of claim 19 , wherein R 2a is chloro or fluoro.

21. The compound of claim 1 , wherein R 2b is halo.

22. The compound of claim 21 , wherein R 2b is chloro or fluoro.

23. The compound of claim 1 , wherein R 3a , R 3b , R 4a and R 4b are each independently H.

24. The compound of claim 1 , wherein R 6 is heterocyclylaminyl.

25. The compound of claim 1 , wherein R 6 is H.

26. The compound of claim 1 , wherein Q is —C(═O)—.

27. The compound of claim 1 , wherein at least one of R 9 or R 10 is H.

28. The compound of claim 27 , wherein each of R 9 and R 10 are H.

29. The compound of claim 1 , wherein

has one of the following structures:

30. The compound of claim 1 , wherein

has the following structure:

31. The compound of claim 1 , wherein each of R a , R b , R 1 , R 2a , R 2b , R 2c , R 3a , R 3b , R 4a , R 4b , R 6 , R 8 , R 8′ , R 9 , R 10 and L 2 are unsubstituted.

32. The compound of claim 1 , wherein the compound has one of the following structures:

33. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2021
From: JANSSEN BIOTECH, INC.
To: ARAXES PHARMA LLC
Reel/Frame 058604/0004 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2021
From: ARAXES PHARMA LLC
To: ARAXES PHARMA LLC; JANSSEN BIOTECH, INC.
Reel/Frame 056969/0864 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2015
From: LI, LIANSHENG; FENG, JUN; WU, TAO; REN, PINGDA; LIU, YI; LIU, YUAN; LONG, YUN OLIVER
To: ARAXES PHARMA LLC
Reel/Frame 035660/0350 →
Continuity (4)
Provisional Application 62052366 · Sep 18, 2014
Provisional Application 62034619 · Aug 7, 2014
Provisional Application 61889460 · Oct 10, 2013
Related Publication 20150239900A1 · Aug 27, 2015